1月6日 - ** 生物制药公司Alumis ALMS.O的股票盘前大涨17.2%，至9.74美元
** ALMS称， (link)，其实验性药物恩夫德替尼（envudeucitinib）在中重度斑块状银屑病患者的两项后期研究中达到了主要目标。
** 在这两项试验中，与安慰剂相比，恩夫替尼在治疗 24 周后皮肤变得更加清晰
** 斑块状银屑病是一种免疫介导的皮肤病，免疫系统过度活跃，导致皮肤细胞生长过快。
** Alumis计划于2026年下半年向美国FDA提交上市申请
** 在过去12个月中，股价累计下跌14.9
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.